Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6...

Full description

Bibliographic Details
Authors: Fernandez Rivera, Constantino, Calvo Rodríguez, María, Poveda, José Luís, Pascual, Julio, Crespo, Marta, Gomez, Gonzalo, Cabello Pelegrin, Sheila, Paul, Javier, Lauzurica, Ricardo, Perez Mir, Mònica, Moreso, Francesc, Perelló, Manel, Andres, Amado, González, Esther, Fernandez, Ana, Mendiluce, Alicia, Fernández Carbajo, Beatriz, Sanchez Fructuoso, Ana, Calvo, Natividad, Suarez, Alejandro, Bernal Blanco, Gabriel, Osuna, Antonio, Ruiz-Fuentes, M Carmen, Melilli, Edoardo, Montero Perez, Nuria, Ramos, Ana, Fernández, Beatriz, López, Verónica, Hernandez, Domingo, Better study
Format: article
Publication Date:2021
Country:España
Institution:Instituto de Salud Carlos III (ISCIII)
Repository:Repisalud
Language:English
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/18521
Online Access:http://hdl.handle.net/20.500.12105/18521
Access Level:Open access
Keyword:bioavailability
clinical practice
pharmacokinetics
renal transplantation
tacrolimus
treatment failure
Biological Availability
Drug Administration Schedule
Graft Rejection
Humans
Immunosuppressive Agents
Kidney Transplantation
Prospective Studies
Tacrolimus
Transplant Recipients
Description
Summary:Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR-Tac (Advagraf) group. Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily dose [TDD]) vs. PR-Tac (61% increase; P 

Similar Items